Effect of omega3 supplementation in women with polycystic ovary syndrome

Not Applicable

• Conditions: polycystic ovary syndrome.; Sclerocystic ovary syndrome Stein-Leventhal syndrome

• Registration Number: IRCT201112318564N1
• Lead Sponsor: Institute for Reproductive Sciences, Research and clinical Center for Infertility

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 64

Inclusion Criteria

females 20-40 years; PCOS diagnostic according to Roterdam criteria and BMI>25; no history about intake of any drug during the last 3 months that may affect the insulin sensitivity or hormonal profile such as: oral contraceptives, glucocorticoids, ovulation induction agents, anti diabetic and anti obesity drugs, estrogenic, antiandrogenic or anti hypertensive medication; not being in any diet in the last 3month; do not have any addiction to tobacco and alcohol; do not taking a Omega-3 supplement in the last 3 months; do not be menopaused; do not use anti-coagulant medicine; do not use anti-depression medication and do not be diabetic and hypothyroidism.
Exclusion criteria: essentially needs for intake of OCP to treatment; do not will to be in the study; do not obey the protocols of the study and do not digest more than 20% of supplements.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Oxidated low density lipoprotein. Timepoint: Before and after intervention. Method of measurement: OxLDL ng/ml Elisa kit -.;SHBG. Timepoint: Before and after intervention. Method of measurement: Elisa kit nmol/L SHBG- Elisa kit.;Free androgen index. Timepoint: Before and after intervention. Method of measurement: Testosteron/SHBG.;Testosteron. Timepoint: Before and after intervention. Method of measurement: Elisa kit nmol/L Testosteron.;Interleukin 6. Timepoint: Before and after intervention. Method of measurement: IL6 pg/ml Elisa kit.;HsCRP. Timepoint: Before and after intervention. Method of measurement: mg/L hsCRP - Elisa kit.